Luliconazole

CAS No. 187164-19-8

Luliconazole( NND-502 )

Catalog No. M12896 CAS No. 187164-19-8

Luliconazole is a broad-spectrum antifungal drug.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 30 In Stock
50MG 28 In Stock
100MG 39 In Stock
200MG Get Quote In Stock
500MG 91 In Stock
1G 142 In Stock

Biological Information

  • Product Name
    Luliconazole
  • Note
    Research use only, not for human use.
  • Brief Description
    Luliconazole is a broad-spectrum antifungal drug.
  • Description
    Luliconazole is a broad-spectrum antifungal drug.(In Vitro):The MICs of LLCZ against the organism measured by a standardized microdilution method using RPMI 1640 medium, were 0.002 μg/ml for T. mentagrophytes TIMM1189 and 0.002 μg/ml for TIMM2789.The minimum inhibitory concentrations (MIC) of luliconazole against Trichophyton spp. (T. rubrum, T. mentagrophytes and T. tonsurans) and Candida albicans are measured by the standardized broth microdilution method.Luliconazole demonstrates great potency against Trichophyton spp. (MIC range: 0.00012-0.002 μg/ml) than the reference agents, with T. rubrum being the most susceptible to it (MIC range: 0.00012-0.00024 μg/ml). Luliconazole is against T. mentagrophytes with MIC values ranging 0.00012-0.002 μg/ml. Luliconazole is also highly active against Candida albicans (MIC range: 0.031-0.13 μg/ml). Further, the MIC of luliconazole against Malassezia restricta is very low (MIC range: 0.004-0.016 μg/ml). (In Vivo):uliconazole (subcutaneous injection; 1, 5 and 25 mg/kg/day) is administered from the beginning of organogenesis (gestation day 7) through the end of lactation (lactation day 20). Luliconazole at 25 mg/kg presents maternal toxicity and embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality). Luliconazole at 5 mg/kg exhibits no embryofetal toxicity. Additionally, at 25 mg/kg/day has no treatment effects on postnatal development in rats.Luliconazole (appliance on skin; 0.02%-1%; 7-14 days) has dose-dependent therapeutic efficacy on skin, it exerts efficacy its even at a concentration of 0.02%, and its efficacy at 0.1% is equal to that of 1% bifonazole creama tinea corporis model (4- and 8-day treatment) and the tinea pedis model (7- and 14-day treatment).
  • In Vitro
    The MICs of LLCZ against the organism measured by a standardized microdilution method using RPMI 1640 medium, were 0.002 μg/ml for?T. mentagrophytes?TIMM1189 and 0.002 μg/ml for TIMM2789.The minimum inhibitory concentrations (MIC) of luliconazole against Trichophyton spp. (T. rubrum, T. mentagrophytes and T. tonsurans) and Candida albicans are measured by the standardized broth microdilution method.Luliconazole demonstrates great potency against Trichophyton spp. (MIC range: 0.00012-0.002 μg/ml) than the reference agents, with T. rubrum being the most susceptible to it (MIC range: 0.00012-0.00024 μg/ml). Luliconazole is against T. mentagrophytes with MIC values ranging 0.00012-0.002 μg/ml. Luliconazole is also highly active against Candida albicans (MIC range: 0.031-0.13 μg/ml). Further, the MIC of luliconazole against Malassezia restricta is very low (MIC range: 0.004-0.016 μg/ml).
  • In Vivo
    Luliconazole (subcutaneous injection; 1, 5 and 25 mg/kg/day) is administered from the beginning of organogenesis (gestation day 7) through the end of lactation (lactation day 20). Luliconazole at 25 mg/kg presents maternal toxicity and embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality). Luliconazole at 5 mg/kg exhibits no embryofetal toxicity. Additionally, at 25 mg/kg/day has no treatment effects on postnatal development in rats.Luliconazole (appliance on skin; 0.02%-1%; 7-14 days) has dose-dependent therapeutic efficacy on skin, it exerts efficacy its even at a concentration of 0.02%, and its efficacy at 0.1% is equal to that of 1% bifonazole creama tinea corporis model?(4- and 8-day treatment) and the tinea pedis model (7- and 14-day treatment). Animal Model:Male specific-pathogen-free (SPF) Hartley guinea pig models of tinea corporis and tinea pedisDosage:0.02%-1% Administration:Appliance on skin; 0.02%-1%; 7-14 days Result:Was sufficiently potent for short-term treatment for dermatophytosis in vivo.
  • Synonyms
    NND-502
  • Pathway
    Microbiology/Virology
  • Target
    Antifungal
  • Recptor
    Antifungle
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    187164-19-8
  • Formula Weight
    354.28
  • Molecular Formula
    C14H9Cl2N3S2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 5 mg/mL (14.11 mM); DMSO: 71 mg/mL (200.4 mM)
  • SMILES
    N#C/C(N1C=CN=C1)=C2SC[C@@H](C3=CC=C(Cl)C=C3Cl)S/2
  • Chemical Name
    (2E)-[(4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene](1H-imidazol-1-yl)acetonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Uchida K, et al. J Infect ChemOthers, 2004, 10(4), 216-219.
molnova catalog
related products
  • Cinobufagin

    Cinobufagin is a selective Na+/K+-ATPase inhibitor. The activity of Cinobufagin is same as ouabain.

  • Triadimefon

    Triadimefon is an azole fungicide ?used to control powdery mildew.

  • Embeconazole

    Embeconazole (R 120758) is a triazole antifungal agent.Embeconazole has strong in vitro activity against clinically important fungi such as Candida, Aspergillus and Cryptococcus neoformans.